Investigating blood cancer risks in patients with ovarian and other solid tumors
Official title: Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
Run by University of Washington · NCT06295965 · Data updated 2026-11-12
This study is trying to see if certain cancer treatments for ovarian and other solid tumors can increase the risk of blood cancers in patients.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | University of Washington Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seattle, Washington) |
| Status | Recruiting |
| Started | January 2, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2031 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT06295965 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a history of ovarian, peritoneal, or fallopian tube carcinoma who have undergone significant chemotherapy or have been treated with PARP inhibitors.
✕Probably not a fit
Patients with a life expectancy of less than 6 months or those without a relevant cancer history may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between clonal hematopoiesis and the emergence of therapy-related myeloid neoplasms in patients diagnosed with ovarian or other solid tumors. Participants will provide blood samples and complete surveys, while their medical records will be reviewed to identify potential risk factors and genetic or environmental influences on the development of blood cancers. The study focuses on patients who have undergone specific cancer treatments, particularly platinum-based chemotherapy or PARP inhibitors.
Why it matters
Potential benefit: If successful, this study could help identify risk factors for blood cancers in patients with solid tumors, leading to improved monitoring and preventive strategies.
How similar studies have gone: While the investigation of clonal hematopoiesis in cancer patients is an emerging field, similar studies have shown promise in identifying risk factors for blood cancers, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and: * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy OR * Subjects who have or have had a solid tumor diagnosis and any of the following: * At least 4 months of exposure to a PARP inhibitor * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm Exclusion Criteria: * Individuals with a life expectancy of less than 6 months
Where it's running
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Elizabeth Swisher — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Swisher Lab Research Coordinators
- Email: swisherlabrc@uw.edu
- Phone: 206-616-8927
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted therapy for advanced solid tumors based on genetic testing
This study is testing whether matching patients with advanced solid tumors to specific treatments based on their genetic makeup can improve their outcomes when standard options have failed.
-
Imaging with a new radioactive tracer for solid tumors
This study is testing a new imaging method using a special radioactive tracer to see if it can help find tumor cells in patients with solid tumors like ovarian and breast cancers, while also looking at how safe it is and how it relates to certain genetic factors.
-
Automated physical activity program for cancer patients
This study is testing whether a personalized exercise program using wearable technology can help cancer patients be more active compared to regular exercise advice.
-
Using MUC1-activated T cells to treat resistant ovarian cancer
This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.
-
Combining pembrolizumab and bevacizumab with an immune booster for recurrent ovarian cancer
This study is testing a new combination of two cancer drugs, pembrolizumab and bevacizumab, with or without an immune booster, to see if it helps people with recurrent ovarian cancer feel better and live longer.
-
Combining APL-2 with Pembrolizumab and Bevacizumab for Recurrent Ovarian Cancer
This study is testing if a new treatment combining APL-2 with pembrolizumab and bevacizumab can help people with recurrent ovarian cancer feel better and live longer compared to just using bevacizumab alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.